Partner Headlines - BMY

  1. Merck got EU's CHMP

    IBD
  2. Puma Crashes, Roche Rises On Cancer Data News

    IBD
  3. Berenberg Initiates Bristol-Myers Squibb With Hold

    Benzinga
  4. Benzinga's Top Initiations

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. Bristol-Myers Squibb to Present Data at 2015 American Society ...

    Benzinga
  7. Making Money With Charles Payne: 05/8/15

    FoxBusiness
  8. Bayer Enters Into Collaboration With Isis For Enhancing Its Drug ...

    GuruFocus
  9. Merck's Stock Price, Dividend Yield Beating S&P 500

    IBD
  10. Bristol-Myers Squibb

    IBD
  11. Vanguard Adds to Four of Its Largest Stakes

    GuruFocus
  12. Merck Jumps, United Therapeutics Drops On Q1 Earnings

    IBD
  13. Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

    IBD
  14. Stock Futures Mixed, Nasdaq Up; Apple, Vasco, Merck Rising

    IBD
  15. Earnings Scheduled For April 28, 2015

    Benzinga
  16. Nasdaq Leads Market Lower As Medical Stocks Tumble

    IBD
  17. 4 Drug Giants Reporting Earnings This Week

    IBD
  18. Benzinga's Weekend M&A Chatter

    Benzinga
  19. U.S. Tech, Dollar & Health Care ETFs To Watch This Week

    Benzinga
  20. Benzinga's Top Upgrades

    Benzinga
  21. Cancer Drugs Impress Again

    IBD
  22. CAR-T Therapy Stocks Hit Hard Following AACR Data

    Benzinga
  23. Bristol, Merck Cancer Drugs Strut Their Stuff

    IBD
  24. Bristol-Myers scores again

    IBD
  25. It's A Big Weekend For Biotech

    Benzinga
  26. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  27. Bristol's Opdivo Scores Again Against Lung Cancer

    IBD
  28. Bristol-Myers Up Big After Drug Study Stopped Early

    Benzinga
  29. AstraZeneca's Onglyza Ups Risk Of Death, FDA Says

    IBD
  30. Benzinga's M&A Chatter for Monday April 13, 2015

    Benzinga
  31. Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of ...

    Benzinga
  32. UPDATE: USDA Approves Supplimental Biologics License

    Benzinga
  33. USDA Accepts Supplemental Biologics License Application for Yervoy ...

    Benzinga
  34. Bristol Myers Reports Data Supporting Clinical Development Of ...

    Benzinga
  35. Biotech Pharmacyclics Spikes On Buyout Rumors

    IBD
  36. Bristol-Myers Squibb Launches Phase III Trial Of HIV Drug

    Benzinga
  37. Lannett Joins Big-Game Hunt For Drugmaker Acquisitions

    IBD
  38. Bristol-Myers goes for the gut

    IBD
  39. Drugmaker Mylan Takes Part In Pharma Feeding Frenzy

    IBD
  40. Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals ...

    GuruFocus
  41. Pharma M&A: Bristol-Myers, Valeant Make Deals

    IBD
  42. Morning Market Gainers

    Benzinga
  43. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  44. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  45. Strong Dollar Weakens Views

    IBD
  46. Drugmakers Warn On Dollar

    IBD
  47. Strong Dollar Pins U.S. Corporate Earnings Outlook

    IBD
  48. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  49. Strong Dollar Means Flabby Outlook For Some Overseas

    IBD
  50. Bristol, Pfizer, Novartis Forecasts Face FX Pressures

    IBD
  51. Tuesday Morning Movers: Microsoft, Procter & Gamble Tumble Following ...

    Benzinga
  52. UPDATE: Bristol-Meyers Squibb Posts Upbeat Q4 Results, Issues ...

    Benzinga
  53. Earnings Scheduled For January 27, 2015

    Benzinga
  54. Pharmaceuticals Sector To See High Voltage Action in 2015

    GuruFocus
  55. 3 High-Flying Health Care Stock IPOs To Watch In 2015

    IBD
  56. BRISTOL-MYERS SQUIBB

    IBD
  57. Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman

    Benzinga
  58. Feeling Good With This Med Company

    GuruFocus
  59. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  60. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  61. Celgene Outlook Is Upbeat

    IBD
  62. Celgene, Bristol-Myers Cancer Drug News Lifts Stocks

    IBD
  63. Bristol-Myers Hits 14-Year High On Cancer Drug Trial

    IBD
  64. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  65. Morning Market Gainers

    Benzinga
  66. Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2 ...

    Benzinga
  67. What Investors Should Expect From Portola Pharmaceutical's Upcoming ...

    Benzinga
  68. Jim Cramer Advises His Viewers On Wynn Resorts And Second Sight ...

    Benzinga
  69. Bristol-Myers Squibb and California Institute for Biomedical ...

    Benzinga
  70. 5 Biotech Stocks With Big News Due In January

    IBD
  71. FDA's OKs may prescribe hits

    IBD
  72. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  73. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  74. Celgene drug could gain share

    IBD
  75. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  76. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  77. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
  78. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus
  79. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus
  80. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD
  81. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers ...

    GuruFocus
  82. Screening Pharma Stocks Amid Turnaround

    YCharts
  83. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  84. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  85. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  86. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  87. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  88. Lung cancer drug promising

    IBD
  89. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  90. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  91. Eliquis revives Bristol-Myers

    IBD
  92. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  93. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  94. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  95. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  96. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  97. Earnings Scheduled For October 24, 2014

    Benzinga
  98. Must Watch Stocks for Today

    Benzinga
  99. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  100. Drug ETFs Attractive Buys On Pullback

    Benzinga
Trading Center